Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review.

ABSTRACT:

Background

Platelet transfusion is considered the standard treatment for preventing or controlling severe haemorrhage in Glanzmann thrombasthenia (GT). However, platelet transfusion can have detrimental effects, including the production of anti-GPIIb/IIIa isoantibodies or anti-HLA antibodies (Ab) and platelet transfusion refractoriness. Recombinant activated factor VII (rFVIIa) has been proposed as an alternative treatment to platelet transfusion.

Methods

We analyzed data from 77 case reports including 100 subjects to investigate the effectiveness and safety of rFVIIa in combination with platelets or antifibrinolytics for preventing or treating non-surgical bleeds, as well as surgical and obstetrical procedures in GT.

Results

The dosage of rFVIIa was consistent with p

SUBMITTER: Saultier P 

PROVIDER: S-EPMC11780185 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature